Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence
PHASE2CompletedINTERVENTIONAL
Enrollment
141
Participants
Timeline
Start Date
July 31, 1998
Study Completion Date
June 30, 2001
Conditions
MelanomaNeoplasm Metastasis
Interventions
DRUG
GP100 peptide
DRUG
IL-2
Trial Locations (1)
20892
National Cancer Institute (NCI), Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00001705 - Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence | Biotech Hunter | Biotech Hunter